Suppr超能文献

基于TNM分期和治疗前全身免疫炎症指数比较TPF与TP诱导化疗用于局部晚期鼻咽癌的疗效

Comparison of TPF and TP Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma Based on TNM Stage and Pretreatment Systemic Immune-Inflammation Index.

作者信息

Xiong Ying, Shi Liangliang, Zhu Lisheng, Peng Gang

机构信息

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

出版信息

Front Oncol. 2021 Sep 20;11:731543. doi: 10.3389/fonc.2021.731543. eCollection 2021.

Abstract

PURPOSE

To evaluate the efficacy and toxicity of the two IC (induction chemotherapy) regimens, TPF (taxanes, cisplatin, and 5-fluorouracil) and TP (taxanes and cisplatin) combined with concurrent chemoradiotherapy (CCRT) in locally advanced nasopharyngeal carcinoma (LA-NPC) patients.

METHODS

Ultimately, we enrolled 213 patients at stage III-IVA in this retrospective study. The prognosis of TPF and TP was compared by Kaplan-Meier and Cox proportional hazard regression. The toxicities were evaluated according to CTCAE v4.0 and RTOG criteria.

RESULTS

TPF was found to have a higher 5-year DMFS in stage IVA and N2-3 patients. The optimal value of pretreatment SII was 432.48. A further subgroup analysis revealed that patients in stage IVA combined with SII ≥432.48 showed superior OS (=0.038) and DMFS (=0.028) from TPF. Also, SII was proved to be a prognostic element for PFS (HR 2.801, P=0.018) and DMFS (HR 3.735, P=0.032) in multivariate analysis, and IC regimen (HR 2.182, P=0.049) for predicting DMFS. The rate of grade 3-4 leukopenia (=0.038), neutropenia (=0.021), radiation oral mucositis (=0.048), diarrhea (=0.036), and ear damage (=0.046) were more common in TPF group.

CONCLUSION

Our study revealed that TPF regimen showed a higher 5-year DMFS for stage IVA and N2-3 patients, while for stage III and N0-1, TP might be ample. In high-risk LA-NPC patients (stage IVA combined with pretreatment SII ≥432.48), TPF had a higher 5-year OS and DMFS, with more grade 3-4 toxicities, but most of them were endurable.

摘要

目的

评估两种诱导化疗(IC)方案,即TPF(紫杉烷、顺铂和5-氟尿嘧啶)和TP(紫杉烷和顺铂)联合同步放化疗(CCRT)在局部晚期鼻咽癌(LA-NPC)患者中的疗效和毒性。

方法

在这项回顾性研究中,我们最终纳入了213例III-IVA期患者。通过Kaplan-Meier法和Cox比例风险回归比较TPF和TP的预后。根据CTCAE v4.0和RTOG标准评估毒性。

结果

发现TPF方案在IVA期和N2-3期患者中具有更高的5年无远处转移生存率(DMFS)。治疗前系统性免疫炎症指数(SII)的最佳值为432.48。进一步的亚组分析显示,IVA期合并SII≥432.48的患者接受TPF方案时总生存期(OS)(=0.038)和无远处转移生存率(DMFS)(=0.028)更佳。此外,在多变量分析中,SII被证明是无进展生存期(PFS)(风险比[HR] 2.801,P = 0.018)和无远处转移生存率(DMFS)(HR 3.735,P = 0.032)的预后因素,而IC方案(HR 2.182,P = 0.049)可用于预测DMFS。3-4级白细胞减少(=0.038)、中性粒细胞减少(=0.021)、放射性口腔黏膜炎(=0.048)、腹泻(=0.036)和耳部损伤(=0.046)的发生率在TPF组中更为常见。

结论

我们的研究表明,TPF方案在IVA期和N2-3期患者中显示出更高的5年无远处转移生存率,而对于III期和N0-1期患者,TP可能就足够了。在高危LA-NPC患者(IVA期合并治疗前SII≥432.48)中,TPF方案具有更高的5年总生存期和无远处转移生存率,且3-4级毒性更多,但大多数是可耐受的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9db/8488348/205ed969a4c0/fonc-11-731543-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验